Compare XERS & NCNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XERS | NCNO |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2021 | 2022 |
| Metric | XERS | NCNO |
|---|---|---|
| Price | $8.23 | $18.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 16 |
| Target Price | $10.83 | ★ $26.07 |
| AVG Volume (30 Days) | 1.9M | ★ 2.5M |
| Earning Date | 05-07-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 100.00 | ★ 115.15 |
| EPS | 0.01 | ★ 0.12 |
| Revenue | $49,590,000.00 | ★ $594,781,000.00 |
| Revenue This Year | $34.37 | $9.53 |
| Revenue Next Year | $22.86 | $8.97 |
| P/E Ratio | $821.00 | ★ $147.08 |
| Revenue Growth | ★ 142.67 | 10.01 |
| 52 Week Low | $4.87 | $13.80 |
| 52 Week High | $10.08 | $33.92 |
| Indicator | XERS | NCNO |
|---|---|---|
| Relative Strength Index (RSI) | 54.38 | 61.61 |
| Support Level | $8.00 | $14.04 |
| Resistance Level | $8.42 | $18.66 |
| Average True Range (ATR) | 0.33 | 0.77 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 24.00 | 83.33 |
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Ncino Inc is a provider of cloud-based software for financial institutions. It is focused on developing the nCino Platform to transform commercial and small business lending for community and regional banks in the U.S. With the company's platform financial institutions can Operate More Intelligently, Improve Efficiency, Elevate Employee and Client Experiences, and Manage Risk and Compliance Continuously Rather Than Reactively. It has built and acquired technology, including SimpleNexus, DocFox, FullCircl, ILT, Visible Equity, FinSuite, and Sandbox Banking, to augment the nCino Platform's capabilities for mortgage lending, onboarding, account opening, indirect auto lending, and analytics and AI. The company operates as one operating segment.